



Received: 3. November 2010
Accepted: 26. January 2011.
END STAGE HEART FAILURE
– TRANSPLANTATION OR LVAD?
Jozica Šikić
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Summary
Heart failure is a complex clinical syndrome that can result from any structural or 
functional cardiac disorder that impairs the ability of the ventricle to fill or eject blood. 
According to the data from the International Society for Heart and Lung Transplantati-
on registry, the half-life of patient survival after heart transplantation has progressively 
improved from 8.9 years in 1982 to a projected half-life of approximately 11 years from 
2002 to 2006. The peak VO2 (VO2max) is the most objective assessment of functional 
capacity in patients with  heart failure, and may be the best predictor of when to list 
a patient for cardiac transplantation. Mechanical cardiac support devices may be im-
planted in patients, in whose cases all other pharmacological therapies (oral medicati-
ons and intravenous inotropes) for severe heart failure, as well as non-pharmacological 
support with intraaortic balloon pump counterpulsation, have failed. Left ventricular 
assist device provide support of the left ventricular function, causing reverse ventricular 
remodeling and permanent improvement of left ventricular function. End stage heart 
failure is not an end of life, since heart transplantation, better medications and devices, 
including ventricular assist devices implantations, offer patients a better quality and an 
appreciable extension of life.
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1 The definition of heart failure
Heart failure (HF) is a complex clinical syndrome that can result from any struc-
tural or functional cardiac disorder that impairs the ability of the ventricle to fill or 
eject blood [1]. The most common cause of heart failure is the left ventricular systolic 
dysfunction (about 60%). 
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The right ventricular systolic dysfunction is usually due to the left ventricular 
systolic dysfunction. However, it can also develop as a consequence of ventricu-
lar infarction, pulmonary hypertension, chronic severe tricuspid regurgitation, or 
arrhythmogenic right ventricular dysplasia. The diastolic left ventricular dysfun-
ction has become a more common reason of heart failure. The American College of 
Cardiology and American Heart Association (ACC/AHA) have developed a classi-
fication of heart failure based upon the evolution and progression of the disease. 
Stage A includes patients at risk of developing heart failure, but who have no struc-
tural heart disease at present. The management strategy is the prevention of heart 
failure. Stage B includes patients with structural heart disease without symptoms. 
The management goal is the prevention of left ventricular remodeling leading to 
heart failure. Stage C includes patients with a structural heart disease with current 
or prior symptomatic heart failure. They may be treated with pharmacological the-
rapy. Cardiac resynchronization therapy may be added. Stage D includes patients 
with severe refractory heart failure [1]. This classification system is a complement 
and does not replace the New York Heart Association (NYHA) functional classifi-
cation. The important goal of it is that the risk factors and structural changes for 
the development of HF and the therapeutic interventions performed even before 
the appearance of the left ventricular dysfunction or symptoms should reduce the 
morbidity and mortality from HF.
The NYHA functional classification scheme is used to assess the severity of fun-
ctional limitations, and it correlates fairly well with the prognosis.
2 Indication for transplantation
In the 2008 report from the Registry of the International Society for Heart and 
Lung Transplantation (ISHLT), it is estimated that annually, more than 5,000 heart 
transplants are performed worldwide (including more than 2,000 not reported) [2]. 
The majority of centers perform between 10 and 19 heart transplants per year. The 
average recipients’ age ranges from 50 to 59.
The ACC/AHA and European Society of Cardiology (ESC) guidelines include 
the following indications for cardiac transplantation: [1,3].
Absolute indications:
1) Hemodynamic disorder due to HF
2) Refractory cardiogenic shock 
3) Dependence on intravenous inotropic support to maintain organ perfusion 
4)  Peak VO2 lower than 10 mL/kg per minute 
5) Severe symptoms of ischemia that consistently limit routine activity and are not 
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amenable to coronary artery bypass surgery or percutaneous coronary inter-
vention
6) Recurrent symptomatic ventricular arrhythmias refractory to all therapeutical 
modalities
Relative indications:
1) Peak V02 of 11 to 14 mL/kg per minute (or 55 % predicted) and major limitation 
of a patient’s daily activities 
2) Recurrent unstable ischemia not amenable to other intervention 
3) Recurrent instability of fluid balance/renal function not due to patient non-com-
pliance with medical regimen
Insufficient indications:
1) Low left ventricular ejection fraction 
2) History of functional class II or IV symptoms of HF 
3) Peak VO2 over 15 mL/kg per minute (or over 55% predicted) with no other indi-
cations
Ventricular assist devices (VADs) can provide mechanical support to “bridge” 
selected patients to transplantation; especially those on the waiting list with a high 
level of mortality expectation.
3 Prognosis after heart transplantation
After transplantation, there is significant mortality prospect in the first six mon-
ths, followed by a mortality rate of about 3.5 percent per year. According to the data 
from the ISHLT registry, the half-life of patient survival after heart transplantation 
has progressively improved from 8.9 years from 1982 to 1991 to 10.3 years from 1992 
to 2001, and to a projected half-life of approximately 11 years from 2002 to 2006 [2]. 
The controlled trials of patients with stable NYHA class III to IV HF have demon-
strated mortality benefit from medical management including angiotensin conver-
ting enzyme (ACE) inhibitor therapy, beta-blocker therapy, aldosterone antagonist 
therapy, implantable cardioverter-defibrillator (ICD) and cardiac resynchronization 
therapy (CRT); often a combination of CRT+ICD [4]. The predictors of death wit-
hin two months of status 1 candidates included status 1A, mechanical ventilation, 
inotropic and intra-aortic balloon pump support, pulmonary capillary wedge >20 
mmHg and serum creatinine >1.5 mg/dl, failed cardiac transplant, valvular cardio-
myopathy, age >60 years, weight ≤70 kg, and lack of ICD on the day of listing. One-
year survival for status 1 candidates improved from 49.5 to 69.0 percent; for status 
2 candidates, it improved from 81.8 to 89.4 percent. The peak VO2 (VO2max) is the 
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most objective assessment of functional capacity in patients with HF, and may be 
the best predictor of when to list a patient for cardiac transplantation. The 2002 task 
force of the ACC/AHA recommended the use of exercise testing with ventilatory gas 
analysis for this purpose [5]. The others risk models are Heart Failure Survival Score 
(HFSS), including: presence or absence of coronary artery disease; resting heart rate; 
left ventricular ejection fraction; mean arterial blood pressure; presence or absence 
of an interventricular conduction delay on ECG; serum sodium; peak VO2; and an 
invasive version with pulmonary capillary wedge pressure. Seattle Heart Failure 
Model in contrast of HFSS included ICDs and CRT. 
4 Indication for left ventricular assist device  (LVAD)
In the 2006 Heart Failure Society of America (HFSA) guidelines, the 2005 ACC/
AHA HF guidelines with 2009 focused update, and the 2008 ESC HF guidelines 
recommended [1,3] that patients awaiting heart transplantation, who have become 
refractory to all means of medical circulatory report, should be considered for a 
mechanical support device as a bridge to transplantation [6]. Destination therapy 
has been recommended for highly selected patients with severe HF refractory to 
conventional therapy, who are not candidates for heart transplantation, and parti-
cularly those who cannot have any approvement from intravenous inotropic sup-
port at an experienced HF center [6]. The 2008 ESC guidelines (although experience 
is limited) considered these devices for long-term use when no definite procedure 
is planned [3]. Mechanical cardiac support devices may be implanted in patients 
who have experienced no clinical improvement from pharmacological therapies for 
severe HF, including oral medications, and intravenous inotropes, and non-phar-
macological support with intraaortic balloon pump counterpulsation. The main 
criteria for selection of patients are as follows: a) active heart transplant candidate; 
b) maximal inotropic support, with or without Intra-aortic balloon pump (IABP); c) 
systolic blood pressure <80 mmHg with a cardiac index below 2.0 L/min per m2 or 
a pulmonary capillary wedge pressure over 20 mmHg [7].
5 Prognosis after LVAD implantation
The LVADs are associated with the least morbidity and the best chance for re-
habilitation and recovery before and after transplantation in patients requiring a 
prolonged support. An important consideration is that the device be implanted 
before developing secondary end-organ damage. In case of irreversible end-organ 
damage (especially renal dysfunction), there will be no improvement of a patient’s 
clinical status. A screening risk score to predict operative mortality after device 
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implantation are as follows: indication for ventilator support (4 points); postcardi-
otomy shock (2 points); the implantation of temporary LVAD prior to HeartMate 
(2 points); central venous pressure >16 mmHg (1 point) and prothrombin time >16 
seconds (1 point). A risk score >5 were associated with a significantly greater ope-
rative mortality than lower score (46 versus 12 percent). Patients with low (0 to 4), 
intermediate (5 to 7) or high (8 to 10) risk score had increasing mortality rates (8, 32, 
and 49 percent) and decreasing rates of successful bridging to transplantation (89, 
65, and 49 percent) [8].
LVAD provide support of the left ventricular function only; the management of 
the right ventricular function is therefore very important, and the goal has to be the 
management of pulmonary vascular resistance. LVAD support reverse ventricular 
remodeling and cause permanent improvement in left ventricle function, causing 
regression of myocyte hypertrophy and fibrosis, improvement in myocyte contracti-
lity, restoration of beta-adrenergic receptors, normalization of calcium metabolism, 
altered expression of genes involved in processes such as myocyte metabolism and 
apoptosis [9-13]. This structural reverse remodeling is complete by about 40 days, 
with evidence of clinical benefit and an improvement in the quality of life [14]. The-
se data suggest that human myocytes have the capability of undergoing beneficial 
functional and electrophysiological changes and an increase in contractility and he-
modynamic improvement [12,13,15]. 
End stage heart failure is not an end of life, since heart transplantation, better 
medications and devices, including VADs implantations, offer patients a better qua-
lity and an apreciable extension of life.
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Sažetak
Terminalna faza zatajenja srca – transplantacija ili LVAD
Zatajenje srca kompleksni je klinički sindrom, a može se razviti kao posljedica bilo kojeg 
strukturalnog ili funkcionalnog poremećaja koji utječe na punjenje klijetki i ispumpavanje krvi. 
Prema podacima ISHLT registra, poluvrijeme preživljavanja nakon srčane transplantacije pro-
dužilo se s 8,9 godina u 1982. na oko 11 godina u razdoblju između 2002. i 2006. Vršni VO2 
(VO2max) najobjektivniji je parametar u procjeni težine zatajenja srca i mogao bi biti najbolji 
prediktor stavljanja bolesnika na transplantacijsku listu. Mehanička srčana potpora indicirana je 
u bolesnika u kojih se farmakološkom terapijom (oralnom i parenteralnom) te nefarmakološkom 
s intraaortnom balon pumpom ne ostvari adekvatno poboljšanje kliničkog statusa bolesnika. 
LVAD potpora je lijevom srcu, a može dovesti do remodeliranja i trajnog poboljšanja funkcije 
lijeve klijetke. Terminalna faza zatajenja srca nije i kraj života jer transplantacija, noviji farmako-
loški pripravci i mehanička potpora, uključujući i VAD, bolesnicima omogućuju bolju kvalitetu 
i produžetak života.
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